SAB Biotherapeutics, Inc.
No SEC Form 4 filings for $SABS in the last 30 days.
See all $SABS insider activity →SAB Biotherapeutics, Inc. (SABS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes MIAMI, Oct. 13, 2026 (GLOBE NEWSWIRE) -- SAB Biother
SAB Biotherapeutics (SABS) announced FDA Fast Track designation for SAB-142, a therapy for Stage 3 type 1 diabetes. The designation aims to expedite development and review. SAB-142 is in Phase 2b trials, with data expected in 2H 2027. The company aims to address unmet medical needs in type 1 diabetes.
SAB Biotherapeutics, Inc. disclosed via an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and related entities may be deemed to beneficially own 22,637,108 shares and 2,286,301 shares, respectively. Holdings include common stock plus conversion/exercise shares from Series B Preferred and related warrants within 60 days, capped at 9.99% voting ownership by blocking provisions.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning SABS (SAB Biotherapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent SABS coverage spans financial news, regulation and market movers.
Regulatory approval accelerates development timeline and reduces perceived risk.
Fast Track status is expected to accelerate development and improve market perception of SAB Biotherapeutics.
The filing signals a large, structured position with a hard 9.99% voting cap, limiting immediate control but keeping conversion and warrant optionality within 60 days.
The grant is supportive for SAB-142’s Stage 3 assessment program, but it is not a new efficacy or regulatory milestone.
Routine corporate governance disclosure; no new operating, financial, or regulatory catalyst is provided beyond voting outcomes.
AlphAI scores every news story that mentions SABS with an AI model for sentiment and relevance, and aggregates insider trades from SAB Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SAB Biotherapeutics, Inc. (SABS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes MIAMI, Oct. 13, 2026 (GLOBE NEWSWIRE) -- SAB Biother
1 min readSAB Biotherapeutics (SABS) announced FDA Fast Track designation for SAB-142, a therapy for Stage 3 type 1 diabetes. The designation aims to expedite development and review. SAB-142 is in Phase 2b trials, with data expected in 2H 2027. The company aims to address unmet medical needs in type 1 diabetes.
2 min readSAB Biotherapeutics, Inc. disclosed via an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and related entities may be deemed to beneficially own 22,637,108 shares and 2,286,301 shares, respectively. Holdings include common stock plus conversion/exercise shares from Series B Preferred and related warrants within 60 days, capped at 9.99% voting ownership by blocking provisions.
4 min readSAB Biotherapeutics (NASDAQ:SABS) said Breakthrough T1D awarded a research grant to support PRISE-hATG, a clinical assessment of SAB-142 in Stage 3 type 1 diabetes patients, according to the companies. SAB-142 aims to preserve C-peptide and modulate immune responses. Barclays initiated coverage on June 24 with an Overweight rating and $13 target price.
2 min readSAB Biotherapeutics, Inc. (SABS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001833214 0001833214 us-gaap:CommonStockMember 2026-06-18 2026-06-18 0001833214 sabs:WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2026-06-18 2026-06-18 0001833214 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISS
2 min readChardan Capital raised its price target for SAB Biotherapeutics (NASDAQ:SABS) to $16.00 from $14.00 and reiterated a “buy” rating, according to a Wednesday research note cited by Benzinga. The target implies 337.16% upside versus the stock’s current price. Other firms’ targets ranged from $10 to $12, while one reiterated a “sell (d+)”.
3 min readBrokerage firms recently updated SAB Biotherapeutics (NASDAQ: SABS) ratings and targets. Citigroup and Jefferies initiated coverage with “buy” ratings and $11 price targets (5/20–5/22/2026). HC Wainwright raised its target to $10 and kept “buy” (5/12). Rodman & Renshaw reaffirmed “buy” with a $13 target (4/2 and 5/11). Zacks upgraded to “hold” (5/11); Weiss reaffirmed “sell (d+)” (4/10).
2 min readSAB Biotherapeutics reported its first-quarter research and development expenses as $13.4 million. This financial detail is important for investors and analysts tracking the company's operational costs and strategic investments in its drug development pipeline. The information, identified by the stock symbol SABS, provides insight into the company's financial activities.
2 min read-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-
3 min read-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the ...
2 min read
